BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19923690)

  • 1. Tumor control probability (TCP) in prostate cancer: role of radiobiological parameters and radiation dose escalation.
    Ahmad S; Vogds BJ; McKenna F; Vlachaki MT
    J Xray Sci Technol; 2009; 17(4):347-54. PubMed ID: 19923690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tumor repopulation on radiotherapy planning.
    Wang JZ; Li XA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer.
    Xiong W; Li J; Ma CM
    Phys Med Biol; 2005 Apr; 50(7):1483-92. PubMed ID: 15798338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
    Luxton G; Hancock SL; Boyer AL
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity modulated radiation therapy versus three dimensional conformal radiation therapy for treatment of high grade glioma: a radiobiological modeling study.
    De La Fuente Herman T; Ahmad And S; Vlachaki MT
    J Xray Sci Technol; 2010; 18(4):393-402. PubMed ID: 21045276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
    Dicker AP; Lin CC; Leeper DB; Waterman FM
    Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
    D'Souza WD; Thames HD; Kuban DA
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures.
    Mavroidis P; Ferreira BC; Shi C; Lind BK; Papanikolaou N
    Phys Med Biol; 2007 Jul; 52(13):3817-36. PubMed ID: 17664579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data.
    Levegrün S; Jackson A; Zelefsky MJ; Skwarchuk MW; Venkatraman ES; Schlegel W; Fuks Z; Leibel SA; Ling CC
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1064-80. PubMed ID: 11704332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMRT versus conventional 3DCRT on prostate and normal tissue dosimetry using an endorectal balloon for prostate immobilization.
    Vlachaki MT; Teslow TN; Amosson C; Uy NW; Ahmad S
    Med Dosim; 2005; 30(2):69-75. PubMed ID: 15922172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AL; Dong L; Kamat A; Pisters L; Kuban DA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):14-9. PubMed ID: 15629589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.
    van Baardwijk A; Bosmans G; Bentzen SM; Boersma L; Dekker A; Wanders R; Wouters BG; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1103-10. PubMed ID: 18258382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal tissue complication probability: does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma.
    Basu KS; Bahl A; Subramani V; Sharma DN; Rath GK; Julka PK
    J Cancer Res Ther; 2009; 5(2):78-84. PubMed ID: 19542662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.